Aptiganel / Cerestat: Overview

Modified on 2009/10/14 21:50 by admin
Research into an experimental stroke drug has been halted after study participants showed no signs of improvement and in some cases died after using the medication. Aptiganel, also known as cerestat, was given to 628 stroke patients for a period of three months. The results, published in the Journal of the American Medical Association, revealed that over twenty percent of those given the drug died.

Cerestat is given to victims of ischemic strokes. Such strokes can occur when clots or narrowed arteries reduce blood flow to the brain. Approximately eighty percent of all strokes are of the ischemic variety.

Cerestat is part of a group of experimental drugs known as neuroprotective medicines.

See your doctor if you have experienced serious health problems after receiving this drug. In addition, it may be important to contact an attorney who can help you protect your legal rights. Please keep in mind that there may be time limits within which you must commence suit.

See Also

  1. Stroke Drugs: Overview
  Name Size